Clinical guide for using capsule sponge tests in the upper GI endoscopy pathway

Scope

A capsule sponge test is a non-endoscopic test that involves the collection of oesophageal cells for cytopathology and immunostaining. This is a swallowable cell collection sponge, contained within a capsule, with an attached string/thread. The capsule is ingested by the patient and dissolves in the stomach, at which point the internal sponge starts to expand. After approximately 7 minutes, the sponge will have fully expanded and is then retrieved using the attached string; as the sponge is retrieved, cells are collected from the lining of the oesophagus and the sponge is sent for laboratory testing to detect Barrett’s oesophagus.

Cytosponge™ is a capsule sponge test that was developed by Medtronic. It consists of a tethered sponge in a capsule that is swallowed and when brought up, it collects oesophageal cells.

EndoSign® is a capsule sponge test that was developed by Cyted in 2023. It works in the same way as Medtronic’s Cytosponge™ device, with the addition of an applicator. The EndoSign® device applicator is designed to hold a pre-bunched thread that allows the user to deposit the capsule and pre-bunched thread onto the patient’s mouth. The applicator is held externally by the patient during the procedure.

Samples collected using the abovementioned cell collection devices are further assessed for diagnosis of intestinal metaplasia (TFF3) and dysplasia (atypia and p53).

During the Covid-19 pandemic, endoscopy waiting lists increased significantly in the NHS in England. Although the majority of these people will not have cancer or other serious pathology, this guidance details how Cytosponge™ and EndoSign® capsule sponge tests can be used to prioritise access to upper GI endoscopy for patients referred to secondary care with reflux symptoms. Identifying those most at risk of Barrett’s oesophagus and oesophago-gastric (OG) cancers will support services to prioritise those patients who are most at risk of serious pathology, whilst minimising the number of upper GI endoscopy procedures required.
This document provides guidance for the use of Cytosponge™ and EndoSign® in the upper GI endoscopy pathway for patients referred with symptoms of gastro-oesophageal reflux. Pathological assessment of the Cytosponge™ and EndoSign® samples will be carried out centrally by the company Cyted. Details of this are included in this guidance.

The NHS Cancer Programme is working with Cancer Alliances to establish capsule sponge test clinics to test and develop the evidence base for this technology, in addition to supporting the restoration of endoscopy services during the Covid-19 pandemic. Cytosponge™ was introduced at the start of the pilot as the only available product on the market. EndoSign® is a newly available device that can be used in place of Cytosponge™.

**Clinical evidence and data on Cytosponge™ and EndoSign®**

As the cell collection methodology is the same for both Cytosponge™ and EndoSign®, the pivotal evidence base is derived from the Cytosponge™ device. Cytosponge™ is a CE marked device that has been used in research studies since 2015 and there are several publications showing the clinical evidence summarised below. EndoSign® is a UKCA and CE marked device available commercially since June 2023. Both devices utilise identical biomarker tests carried out by Cyted.

- There have been three clinical trials that demonstrate the safety, acceptability and diagnostic accuracy of Cytosponge™ to detect Barrett’s Oesophagus. There are some evidence gaps for its use in secondary care, but the evidence has been deemed strong enough by the NHS Cancer Programme’s Expert Advisory Group for Innovation and the Clinical Advisory Group for a pilot roll-out. The evidence gaps will be addressed through the evaluation.

- Applicability to secondary care: the feasibility study BEST1 was conducted in 504 patients in 11 general practices [PMID: 20833740], accuracy study BEST2 performed in secondary care in >1,400 patients [PMID: 25634542] and the randomised study BEST3 involved >1,650 Cytosponges™ administered in 72 GP surgeries [Gastro 2019,156;S284 & PMID: 30075763]. Data from the control arm of BEST2 support the use of Cytosponge™ in secondary care, however the data is not randomised [PMID: 25634542].

- Safety: Cytosponge™ administration is very safe [PMIDs: 19651633, 20833740, 25634542, 17566045, Gastro 2015, 148(4);S16]. The detachment rate is currently
quoted at <1:5,000 with easy retrieval at endoscopy. The commonest side-effect is sore throat which resolves within a few days. It avoids the risks associated with sedation in endoscopy and many patients prefer the convenience and speed of this test compared with endoscopy. Furthermore, it can be delivered in a more Covid-secure environment.

- **Acceptability:** The Cytosponge™ procedure scored a median score of 6.0 (95%CI 5.0-8.0) on a visual analogue scale from 0 (worst experience) to 10 (best experience), which is higher than endoscopy [PMIDs: 19651633, 20833740, 25634542, 17566045, Gastro 2015, 148(4);S16] and 8.6/10 in the recently completed BEST3 study [Gastro 2019,156;S284].

- **Cytosponge™:** TFF3 test is accurate for diagnosing Barrett’s oesophagus with a sensitivity of approximately 80% (intention to treat analysis) and specificity of >92%. When patients are recalled if the sample is inadequate (12-15%) the sensitivity is 94% (PMID: 25634542).

- **Cytosponge™** can also diagnose other clinically relevant oesophageal conditions including early cancer, eosinophilic Oesophagitis (EoE), oesophageal candida, oesophagitis, and *H.pylori*, if present in the proximal stomach.

- **A TFF3 positive Cytosponge™** indicates intestinal metaplasia (IM) - this is often from Barrett’s but can also arise from IM of the gastric cardia which can indicate more extensive gastric IM, a premalignant condition. In the BEST3 study this has led to an early diagnosis of gastric cancer in one case.

- **Cost-effectiveness:** A full health economic analysis is underway for BEST3 (PMID: 34195582) and cost effectiveness and value for money will be looked at as part of the evaluation of this pilot.

- **EndoSign®** has undergone performance and safety testing. Performance verification studies carried out in volunteers has shown 100% sufficient cellularity for diagnosis. In addition, an independent mechanical safety testing has demonstrated an equivalent or higher Process Capability Index (Cpk) value, indicating equivalent or lower detachment per million devices compared to Cytosponge™. The detachment rate for EndoSign® is estimated to be less than 0.01 in 1,000,000.
Target population and exclusions

This guidance is specific for the use of Cytosponge™ and EndoSign® in patients referred with reflux symptoms with no alarm symptoms by general practitioners to secondary care on a diagnostic upper GI endoscopy pathway.

Inclusion criteria for Cytosponge™ and EndoSign®:

- Patients with symptoms of reflux including:
  - Heartburn (burning sensation on chest usually after eating),
  - Regurgitation (an unpleasant sour taste in mouth caused by stomach acid)
  - Waterbrash (excessive salivation)

Exclusion criteria for Cytosponge™ and EndoSign® (absolute contraindications):

- **Alarm symptoms:**
  - dysphagia
  - dyspepsia and weight loss
  - dyspepsia and anaemia
- Previous cancer of the oesophagus
- Patient with a diagnosis of an oropharyngeal, oesophageal or gastro-oesophageal tumour
- Patient who has had treatment to the oesophagus e.g. photo dynamic therapy, endoscopic mucosal resection, radio frequency ablation, surgery
- Patient known to have oesophageal varices or cirrhosis of the liver
- Patient with a known anomaly of the oesophagus e.g. webbing, pouch, stricture etc.
- Patients who are pregnant (relative contraindication, Cytosponge™ and EndoSign® not harmful but may not be appropriate)
- Patients unable to give consent
- Patients who have had a stroke or any other neurological disorder where their swallowing has been affected
- Patients who have had a myocardial infarction in the last 3 months.
Patients to consider as having relative contra-indications to Cytosponge™ and EndoSign® use:

- Patients who have had fundoplication may be candidates for Cytosponge™ and EndoSign® but may have reflux symptoms post procedure.

**Triaging process**

A dyspepsia Nurse or Gastroenterologist will identify appropriate patients referred to secondary care for endoscopy that meet the criteria for the Cytosponge™ or EndoSign® test. A triaging appointment will be carried out by the nurse over the phone to check their eligibility. A specified triage assessment form (provided nationally) should be completed.

Suitable patients should be invited for a Cytosponge™ or EndoSign® test and provided with a patient leaflet (paper or online).

**Preprocedural preparation**

Patients should be advised to be nil by mouth 4 hours prior to the appointment for the Cytosponge™ or EndoSign® test. For patients on anticoagulant medication, specific instructions should be provided.

**Anticoagulation**

For patients on anticoagulation therapy, please follow the appropriate guidance below, which aligns to the BSG guidance on low-risk endoscopy procedures. Please note, this guidance is different to the practice carried out in the BEST trials.

**P2Y12 Receptor Antagonist Antiplatelet Agents e.g. Clopidogrel, Prasugrel, Ticagrelor**

- Continue therapy

**Direct Oral Anticoagulants e.g. Dabigatran, Rivaroxaban, Apixaban, Edoxaban**

- Omit DOAC on morning of procedure

**Warfarin**

- Continue warfarin
- Check INR during the week before endoscopy
  - If INR within therapeutic range, continue daily dose
If INR above therapeutic range (above 3.5), escalate to their responsible physician and reduce daily dose until INR returns to therapeutic range

Consent

This should be undertaken in the same way as consent is obtained for upper GI endoscopy i.e. the completion of an NHS Consent Form 1 and retained in the patient notes. The patient should be asked if they are willing for their anonymised sample and data to be used for research, if so, the research box should be ticked. Ticking this box is essential for the data to be included as part of the evaluation.

Procedure

The Cytosponge™ or EndoSign® may be performed by a trained nurse or healthcare professional that has been assessed and deemed competent to carry out the procedure independently (see below for training requirements).

Before the procedure, please check whether the patient has any swallowing difficulties. If the patient has any dysphagia, they are not eligible for Cytosponge™ or EndoSign® and an endoscopy should be carried out.

Before using a Cytosponge™ or EndoSign®, the device should be inspected, and the expiration date should be checked. Do not use the device if it is damaged or it has expired. If a device looks damaged, such as visible cracks in the capsule or protrusion of the sponge through the capsule, it should be reported to the relevant company.

The patient is asked to sit in a chair and swallow the Cytosponge™ or EndoSign® capsule and string together with some water. For the Cytosponge™ device, the end of the string is attached to a piece of card which the nurse will hold (figure 1). For the EndoSign®, the string is pre-bunched in an applicator that the patient will hold (figure 2). The capsule will be in the patient’s stomach for between 7 and 7½ minutes until it dissolves completely, releasing the sponge inside the stomach. The nurse will then remove the sponge from the patient’s stomach and up through the oesophagus by pulling quickly and gently on the string taking about 1-2 seconds. The patient has the option to have a local anaesthetic spray into their throat before the sponge is removed.
Figure 1: Administration and passage of the Cytosponge™ device to obtain a sample of oesophageal epithelial cells. Drawn by Campbell Medical Illustration (Glasgow, Scotland)

Figure 2: EndoSign® capsule sponge device – applicator and sponge. Image produced by Cyted.
The sponge is then placed in a sample collection kit provided by Cyted and secured with a patient identification label which includes the hospital number, year of birth and sex of the patient. The sample collection kit is accompanied by a patient requisition/request form which should be completed during the clinic. Patient specimens and requisition forms are shipped using a secure courier network to Cyted who will carry out the pathological assessment. Diagnostic results are shared with the requesting clinician using NHS.net emails or an electronic reporting connector within 14 working days from the day of sample receipt in the lab.

In the rare event that the Cytosponge™ or EndoSign® detaches and is retained in the stomach, urgent upper GI endoscopy and removal of Cytosponge™ or EndoSign® must be performed. Please follow local guidance and pathways for removal of foreign body.

In the extremely unlikely event that there is inhalation of the Cytosponge™ or EndoSign® (never happened to date), urgent consultation with interventional respiratory or cardiothoracic teams is required and urgent bronchoscopy will be required.

Please note the following factors when you withdraw the sponge:

- **Blood.** If there is any blood on the sponge this could indicate severe inflammation or cancer. The patient should be referred for endoscopy as urgent two-week wait.

- **Lax string.** You should feel some tension when you withdraw the sponge even if there is a hiatus hernia. A lax string on withdrawal is usually from a poor swallow and therefore may mean the result is inadequate. Please note this on the Cyted request form.

**Discharge and safety netting**

Following the procedure, the patient will be given instructions regarding follow up arrangements and who to contact if there is a query or problem post procedure. The patient will be advised that the results will be available in approximately 2-3 weeks’ time, and this will be communicated by letter and/or telephone by the hospital trust. The report received from Cyted must be formally uploaded onto the patient records. The hospital trust is also responsible for informing the GP or referring clinician via letter of the patient outcome and what follow-up plan has been arranged.
Common symptoms post procedure

The most common side effect of the procedure is a sore throat, and this can be treated with appropriate conservative measures or simple analgesia. Mild abdominal pain and nausea may also be experienced.

Symptoms post procedure that require urgent clinical review

Symptoms such as black stool, significant chest pain, severe throat pain, persistent difficulty swallowing, abdominal pain and difficulty breathing require urgent assessment. If a patient develops these symptoms immediately following the procedure, an assessment should be made urgently by the most senior physician. If a patient develops these symptoms following discharge at home, they should be advised to seek urgent medical attention in their local Accident and Emergency department.

Further follow up will be organised for the patient according to the results (see figure 2). Please correlate results with clinical symptoms and manage accordingly.

Cytopathology results

- Atypia (definite or of uncertain significance) and/or abnormal or equivocal p53. Patient requires endoscopy as urgent two-week wait.

TFF3 results

- TFF3 negative + normal P53, no atypia. Patient managed for dyspepsia according to local trust guidance with follow-up arranged by telephone with safety netting. Current symptomatic management may be continued.
- TFF3 positive only (+normal P53, no atypia). Patient requires routine endoscopic assessment.
- TFF3 Equivocal for Intestinal Metaplasia, Normal P53, no atypia. Patient requires repeat Cytosponge™ or EndoSign® testing in 6-12 months.

Inadequate samples

- Insufficient sample: Patient requires repeat Cytosponge™ or EndoSign® testing or an endoscopy as soon as feasible (within 3 months).
• Squamous cells only, no atypia: This suggests that the device did not reach the stomach. Patient probably requires repeat Cytosponge™ or EndoSign® testing or an endoscopy if Barrett’s or gastro-oesophageal junction pathology needs to be excluded.

Other findings

• Other benign diagnoses/findings e.g. inflammation, candida etc. Patient treated according to clinical judgement

Patients with a negative test result but with ongoing symptoms may be followed-up with an appointment in a dyspepsia clinic where this is locally available or may need to be re-referred for further investigation. This appointment should discuss the management of ongoing symptoms as part of safety netting.
Figure 2: Follow up required for Cytosponge™ or EndoSign® sample results including endoscopy guidance where required

**Test Result**

- **Atypia (definite or of uncertain significance) and/or abnormal/equivocal P53**
  - Yes: 2WW endoscopic assessment
  - No: TFF3
    - Negative: Follow-up as per local dyspepsia guidance with telephone appointment and safety netting. Symptomatic treatment may continue.
    - Positive: Routine endoscopic assessment

- **Inadequate sample (insufficient cells/squamous cells only/TFF3 equivocal)**
  - Repeat test*

- **Other findings e.g. inflammation**
  - Treat according to clinical judgement.

- **Endoscopy guidance inflammation only**: Start or increase PPI. OGD only if clinically indicated. If ulcer slough consider OGD according to symptoms.

- **Endoscopy guidance Eosinophils**:
  - Routine OGD, EoE biopsies.

- **Endoscopy guidance atypia +/- p53 positive**: dedicated UGI list. NBI, if available with near focus and/or acetic acid
  - If normal OGD, no lesion/dysplasia found: Atypia & p53 - be cautious, repeat 3-6 months and ideally in dedicated centre
  - Atypia only - repeat 1 year
  - Atypia only and Barrett's no dysplasia - repeat 6 months

- **Endoscopy guidance squamous atypia**: dedicated UGI list. NBI, lugol if available and inspect oropharynx. Consider biopsies of normal squamous mucosa.
  - Follow up: OGD normal - ENT review to check for dysplasia in the room, pharynx and repeat OGD in 1 year
  - OGD abnormal - according to clinical pathway

- **Endoscopy guidance: preferably dedicated UGI list**
  - If BO found ensure Seattle biopsies taken at baseline endoscopy
  - Follow up: perform surveillance at intervals according to BSG guidelines. See separate clinical guidance for use of Cytosponge™ or EndoSign® in surveillance
Oesophagus-Gastro-Duodenoscopy (OGD) protocol for TFF3+ Cytosponge™ or EndoSign®

- TFF3 is an intestinal metaplasia biomarker not just a Barrett’s marker
- Use narrow-band imaging endoscopy where possible.
- Pay special attention to the distal oesophagus and gastro-oesophageal junction (GOJ) for visible Barrett’s, an irregular z-line which may have more focal intestinal metaplasia.
- Number of gland groups positive for TFF3 are indicative: ≥ 3 expect Barrett’s, < 3 expect irregular z-line/ gastric intestinal metaplasia.

Seattle protocol: 4-quadrant biopsies of every 2cm of Barrett’s
Sydney protocol: 2 biopsies of the antrum of the lesser and greater curvature (in 1 cassette), 2 biopsies of the body of the lesser and greater curvature (in 1 cassette), 1 biopsy of the incisura
Training for Cytosponge™

Training will be organised Medtronic and delivered locally on a one-to-one basis in individual hospital trusts. Clinical leads in each pilot clinic are responsible for ensuring nurses (band 7+ or band 6 if supported by band 7+) with sufficient experience are nominated to undertake training. Training may be completed within one clinic session with 8-10 patients for new nurses with no prior experience of capsule sponge testing.

All staff delivering Cytosponge™ procedures must have completed and passed the training and competency assessment.

Training for EndoSign®

Training will be organised by Cyted and delivered locally on a one-to-one basis in individual hospital trusts. Clinical leads in each pilot clinic are responsible for ensuring nurses (band 7+ or band 6 if supported by band 7+) with sufficient experience are nominated to undertake training. Training may be completed within one clinic session with 8-10 patients for new nurses with no prior experience of capsule sponge testing.

For nurses with prior experience in delivering capsule sponge services, a transition training will be carried out to ensure training on the new device is delivered. Training will be completed within one clinic session with 3-5 patients for transitioning nurses.

All staff delivering EndoSign® procedures must have completed and passed the training and competency assessment.

Evaluation

IQVIA was appointed as an independent evaluator to understand the impact of Cytosponge™ on (1) endoscopy demand, (2) patient outcomes, (3) diagnostic experience, and (4) patient inequalities. A process evaluation and economic evaluation were also undertaken. The final evaluation report is due in autumn 2023.

There are no further data collection requirements for this evaluation. Trusts should use OPCS-4 and SNOMED codes to capture patients who receive a Cytosponge™ or EndoSign®. A separate evaluation for Barrett’s surveillance will be conducted (see Barrett’s surveillance guidance).